|
David, thank you. I've owned VRTX in the past (lost money) and I'm hesistant to jump in again. But something obviously is going on to give the stock price a push (presumably the status of the PI clinical trials). It appears to me that the only reasonable PI to prescribe, at this time, is Viracept (? 2 billion+ dollar market; what? 200,000+ patients) as I cannot see any medical justification to prescribing Crixivan, Norvir, or any other PI. And, based on the earlier posts today, I don't even think I'm even interested in trying Sustiva (terrible drug side-effect profile; how did DD get a 3 mos "fast-tract" FDA approval?). However, I would like to try a regimen that includes Remune (if the clinical trial reports are very good, as suspected, this drug should go "fast-tract" FDA approval, IMO). So, I'm staying long on AGPH and IMNR. PS: Wonder how long it will take for Crix to disappear from the market scene. I don't think that Norvir is going anywhere. Dr. Oliver, what do you think? |
